At a glance
ClinicalIndex Comparison RecordN/ACompleted· 400 enrolled
Drug / intervention
Immediate Release Niacin, Extended Release Niacin, Endotoxindrug
Likely dose
Immediate Release Niacin, Extended Release Niacin, Endotoxin 1000mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study
In Brief
A clinical study evaluating Immediate Release Niacin, Extended Release Niacin, Endotoxin for Healthy Volunteers. Completed, enrolled 400 participants across 1 site.
Detailed Summary
The purpose of this study is to determine genetic factors that affect responses to niacin therapy and endotoxemia in healthy volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedAug 2009
Primary CompletionFeb 2011
TodayJul 2026
First PostedAug 6, 2009
Enrollment StartJun 1, 2007
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 16.9 years ago
Interventions
Immediate Release Niacin, Extended Release Niacin, Endotoxindrug
Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).